CPhI will be presenting its 3rd annual "Pharma IPR India" conference in Mumbai on February 26-28. The conference features speakers from more than a dozen different countries across the world. The complete agenda is as follows:
Day 1: USA, Canada, and Mexico
- Analysing the scope and implications of Inter Partes Review (IPR) in the United States after one year
- Evaluating reverse payment settlement cases and decisions after Actavis
- Determining patent eligibility for a US patent and ascertaining ways to use attorney fees/cost shifting for the benefit of pharmaceutical companies
- Formulating the best litigation strategies in the US to optimise costs for pharma and biopharma companies
- Biosimilars status in the USA
- Evaluating the current regime ofthe Canadian Patent Act
- Mapping the current patent regime and patent linkage by tracking recent patent infringement cases in Mexico
Day 2: Europe, South Africa, Brazil, GCC countries, and Australia/New Zealand
- Overview of current implementation of the Unitary Patent System in Europe, including its coming into force, structure, competence, language, and particularities
- Ascertaining data exclusivity in Europe and understanding implications of SPCs on pharma companies
- Formulating strategies to introduce generic products in the European market if there are unavoidable patents not yet invalidated
- Understanding application of the Doctrine of Equivalents in European patent cases
- Understanding recent changes in patent legislature in South Africa and analysing current IP infrastructure
- Understanding the scope of patent law in Brazil and determining reforms therein impacting pharma and biopharma companies
- Examining patent regimes in GCC countries and basic laws of the market and guidance on how to develop a product for these markets
- Defining devised changes affecting patentability in Australia/New Zealand by updating recent trends to standards of applications and litigation in the industry
Day 3: India, South Korea, Taiwan, China, and Japan
- Determining the current position of post-grant oppositions filed by pharmaceutical companies in India
- Determining grounds for invoking compulsory licenses in India, to determine new growth strategies for generic and multi-national companies
- Understanding patent law and the IP regime in South Korea as they apply to pharmaceuticals
- Highlighting amendments related to the dual invention/utility model system in Taiwan, and enforcement of patent rights and damages under the Taiwan Patent Act of 2013
- Understanding the revised version of "Measures for Compulsory Licensing for Patent Implementation" that came into effect in the Chinese patent law
- Understanding techno-legal aspects involved in the patent system of Japan to facilitate breaking the barriers for the entry of generic companies
The early bird discounted registration rate for the conference is still available, but only until January 31st. For more information or to register, please visit the conference website.
Comments